Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capoten ANDA approvals would render Waxman/Hatch 3-year exclusivity "largely meaningless" -- Bristol suit.

Executive Summary

CAPOTEN ANDA APPROVALS WOULD MAKE WAXMAN/HATCH EXCLUSIVITY "MEANINGLESS," Bristol-Myers Squibb maintains in a recent court filing in a civil case challenging FDA's implementation of the Waxman/Hatch three-year exclusivity provisions for new indications. The suit points out that state and private formularies often encourage or require the substitution of an "AB"-rated generic when one is available without regard to indication. Those substitutions render "any patent protection or non-patent exclusivity rights covering the supplemental indication largely meaningless," Bristol declares.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel